pharmaglobenews

Presbyopia, one of the most prevalent age-related vision disorders, is witnessing significant innovation as pharmaceutical and biotechnology companies advance novel therapies designed to improve near vision and reduce dependence on corrective lenses. According to DelveInsight’s latest Presbyopia Pipeline Insight 2026, more than

DelveInsight’s “Tyrosine kinase 2 (TYK2) Inhibitors Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the TYK2 inhibitors, historical and competitive landscape, as well as its market trends in the United States, EU4 (Germany, France, Italy,

DelveInsight’s “IL-23 Inhibitors Target Population, Competitive Landscape, and Market Forecast–2034” report delivers an in-depth understanding of the IL-23, historical and Competitive Landscape as well as the IL-23 inhibitor market trends in the US, EU4 (Germany, France, Italy, and Spain) and the United

DelveInsight’s “Epilepsy Market Insights, Epidemiology and Market Forecast – 2036” report delivers an in-depth understanding of Epilepsy, historical and forecasted epidemiology as well as the Epilepsy therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom,

DelveInsight’s “Ductal Carcinoma in Situ Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of Ductal Carcinoma in Situ, historical and forecasted epidemiology as well as the Ductal Carcinoma in Situ market trends in the United States, EU5 (Germany, Spain,

DelveInsight’s Infusion Pumps Market report delivers a comprehensive analysis of the market by Type (Volumetric Pumps, Syringe Pumps, Enteral Pumps, Insulin Pumps, Elastomeric Pumps, Implantable Pumps, and Patient-Controlled Analgesia Pumps), by Application (Diabetes, Oncology, Pain Management, Gastroenterology, and Others), by End-User (Hospitals

The chronic refractory cough (CRC) market is projected to witness substantial growth through 2034, driven by an expanding diagnosed patient population, increasing recognition of chronic cough as a distinct clinical condition, and the shortcomings of currently used off-label therapies. Chronic Refractory Cough